Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
Type:
Grant
Filed:
May 26, 2016
Date of Patent:
August 28, 2018
Assignees:
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA
Inventors:
Lori Hazlehurst, Mark McLaughlin, Priyesh Jain, William S. Dalton
Abstract: The present disclosure relates to methods and uses of C-terminal peptides for inhibiting neuronal cell death or dysfunction, such as retinal ganglion cell death or dysfunction, treating retinal degenerative disorders, stroke, CNS and PNS insults. The disclosure also relates to the C-terminal peptides, fusion proteins and compositions thereof.
Type:
Grant
Filed:
July 20, 2016
Date of Patent:
August 28, 2018
Assignee:
The Governing Council of the University of Toronto
Abstract: Disclosed is a method of liberating a peptide, the method comprising a step of bringing a self-aggregate of albumin containing a peptide incorporated therein into contact with a solution that contains a compound represented by Formula (I) or (II) defined in the specification at a concentration of 80 mM to 1000 mM and allowing the peptide to be liberated from the self-aggregate of albumin into the solution.
Abstract: Provided are a synthetic peptide that increases the radiosensitivity of tumor cells and a pharmaceutical composition containing that synthetic peptide. The peptide provided by the present invention is a synthetic peptide having a radiosensitizing peptide sequence including the following amino acid sequence: CX2X3KX5X6X7X8C (wherein, X2 represents K or R, X3 represents S or A, X5 represents S or A, X6 represents R or G, X7 represents R or D and X8 represents S or P); or, a modified amino acid sequence in which one, two or three amino acid residues are substituted, deleted and/or added in that amino acid sequence. In addition, the pharmaceutical composition provided by the present invention is a composition used to increase the sensitivity of tumor cells to radiation in tumor radiation therapy, and contains the synthetic peptide described above.
Type:
Grant
Filed:
May 25, 2016
Date of Patent:
August 14, 2018
Assignee:
TOAGOSEI CO. LTD.
Inventors:
Nahoko Baileykobayashi, Noriko Usami, Tetsuhiko Yoshida
Abstract: A composition which is reversible inhibitor of at least one neuron-specific PDZ domain comprising wherein R is a molecular transporter with or without a linker amino acid; R1 is at least about one amino acid covalently bound; and, R2 is isoleucine, leucine, alanine, phenylalanine, or valine, and methods of use.
Type:
Grant
Filed:
June 28, 2016
Date of Patent:
August 14, 2018
Assignee:
The United States of America, as represented by National Institutes of Health (NIH), U.S. Dept of Health and Human Services (DHHS), NIH Division of Extramural Inventions and Technology Resource (DEITR)
Inventors:
Mark Spaller, John Marshall, Dennis J. Goebel
Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as described in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
Type:
Grant
Filed:
October 1, 2015
Date of Patent:
August 7, 2018
Assignee:
Ocera Therapeutics, Inc.
Inventors:
Eric Marsault, Kamel Benakli, Hamid Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.
Type:
Grant
Filed:
November 13, 2015
Date of Patent:
July 24, 2018
Assignee:
The George Washington University a Congressionally Chartered Not-for-Profit Corporation
Abstract: The present invention provides fusion proteins comprising a mucin-domain polypeptide covalently linked to an active protein that has improved properties (e.g. pharmacokinetic and/or physicochemical properties) compared to the same active protein not linked to mucin-domain polypeptide, as well as methods for making and using the fusion proteins of the invention.
Type:
Grant
Filed:
September 1, 2015
Date of Patent:
July 17, 2018
Assignee:
Alkermes, Inc.
Inventors:
Juan Alvarez, Jean Chamoun, Heather C. Losey
Abstract: The disclosed peptidomimetic macrocycles modulate the activity of MCL-1. Myeloid cell leukemia 1 (MCL-1) is a protein that inhibits cell death. Peptidomimetic macrocycles, pharmaceutical compositions, and methods disclosed herein can be used for the treatment of disease in which MCL-1 is over-expressed, such as cancer. In particular, MCL-1-modulating peptidomimetic macrocycles disclosed herein can be applied in the setting of resistance to BCL-2 family inhibitors, which is often engendered by MCL-1 over-expression or hyper-activation.
Abstract: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
July 10, 2018
Assignee:
The Regents of the University of California
Inventors:
John K. Bielicki, Jan Johansson, Waleed Danho
Abstract: The present invention relates to inhibitors of protein-protein interactions (PPI). Specifically, the present invention relates to a structural informatics approach to designing peptidomimetic macrocycles containing an amino acid “warhead” for ligand-directed covalent modification of cysteine and lysine-containing proteins for the treatment of diseases such as cancer. Further included is the targeting of components of the BCL2 signaling pathway, specifically BCL2-A1 and MCL-1.
Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.
Type:
Grant
Filed:
September 2, 2015
Date of Patent:
July 3, 2018
Assignee:
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Abstract: The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).
Type:
Grant
Filed:
September 26, 2014
Date of Patent:
July 3, 2018
Assignees:
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA, MODULATION THERAPEUTICS, THE SCRIPPS RESEARCH INSTITUTE
Inventors:
Lori Hazlehurst, Christoph Rader, Xiuling Li, Mark McLaughlin
Abstract: The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.
Abstract: Tetrapeptide linkers for reversibly linking a first compound to a amine-containing second compound are described. Compounds containing the tetrapeptide linkers and methods of using the tetrapeptide linkers are also described.
Abstract: Disclosed is a method of determining whether a temperature of a sample has reached a predetermined temperature. The method comprises the steps of: mixing an albumin-containing sample with a peptide reagent comprising a peptide for temperature determination; heating the mixture; detecting an optical change of the mixture; and determining whether the temperature of the mixture has reached the predetermined temperature based on the detection result of the optical change. In the method, a dissociation constant (Kd) of binding of the peptide for temperature determination to albumin is 500 ?M or more, and the peptide for temperature determination comprises a first labeling substance and a second labeling substance.
Abstract: A combination of herbal extracts in aqueous solution that when sprayed into a confined area as a fine mist, chemically neutralizes a wide range of odors including those that are acidic, alkaline, and neutral in nature. While this chemical solution may contain fragrances, odor elimination occurs chemically rather than by masking.
Abstract: The present invention relates to an anticancer composition comprising a peptide that inhibits the proliferation of cancer stem cells present in tumor tissue and that induces apoptosis of such cancer stem cells, and more particularly, to an anticancer peptide that inhibits the activity of NF-?B which is overexpressed specifically in cancer stem cells present in tumors.
Type:
Grant
Filed:
March 3, 2016
Date of Patent:
June 12, 2018
Assignees:
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATION CO., LTD.
Inventors:
Yoon Jeong Park, Chong-Pyoung Chung, Jue-Yeon Lee, Jin Sook Suh
Abstract: The present invention provides a Mitrecin A polypeptide useful in prevention and treatment of one or more bacteria. Also provided is a method to kill or prevent growth of one or more bacteria comprising contacting the one or more bacteria with a Mitrecin A polypeptide. The target bacteria can be selected from the group consisting of a Gram-positive bacterium, a Gram-negative bacterium, or both. In one embodiment, the present invention is drawn to a polynucleotide encoding a Mitrecin A polypeptide, a vector comprising the polynucleotide, a host cell comprising the polynucleotide, or a composition comprising the Mitrecin A polypeptide, the polynucleotide, the vector, or the host cell.